Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

Add time:07/11/2019    Source:sciencedirect.com

SummaryBackgroundBruton tyrosine kinase is a clinically validated target in mantle cell lymphoma. Acalabrutinib (ACP-196) is a highly selective, potent Bruton tyrosine kinase inhibitor developed to minimise off-target activity.

We also recommend Trading Suppliers and Manufacturers of Acalabrutinib Intermediate (cas 1420478-90-5). Pls Click Website Link as below: cas 1420478-90-5 suppliers

Prev:Synthesis and biological evaluation of 4-hydroxy-4-(4-methoxyphenyl)-substituted proline and pyrrolidin-2-ylacetic acid derivatives as GABA uptake inhibitors
Next:Regiospecific synthesis of 15-(4-[123I]iodophenyl)pentadecanoic acid-IPPA via methyl 15-(4-trimethylstannylphenyl)pentadecanoate)